A Study of Gene Polymorphisms Associated With Specific Presentations of Sexual Addiction

Genetic Markers in Sexual Addiction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02844985

Enrollment

2000

Registered

2016-07-26

Start date

2016-08-17

Completion date

2021-12-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Addiction

Keywords

Sexual Addiction, Genomics, Personality, Polymorphism

Brief summary

The study is intended to identify gene polymorphisms significantly associated with specific behavioral- and preoccupation-typologies of sexual addiction, and to identify additional potential genetic markers of sexual addiction. Research subjects with sexual addiction will be identified from the out-patient and in-patient populations of the investigative sites. Research subjects in the Control Group will be identified from the general population and from the student body of selected colleges. Approximately 1100 subjects will be enrolled in the study. Anticipating 10% drop-out, this is intended to generate a population of approximately 500 men and women clinically diagnosed with sexual addiction, and approximately 500 healthy men and women who do not meet diagnostic criteria for sexual addiction nor have psychopathology who will serve as the control population.

Interventions

OTHERNo Intervention

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Sexual Addict Group Age \>= 18 years Participating in sexual addiction treatment program Sexual Addiction Screening Test--Revised (SAST-R) score \>= 11 Meets at least 3 diagnostic criteria for sexual addiction * Control Group Age \>= 18 years SAST-R score \< 6

Exclusion criteria

* Sexual Addiction Group Serious mental illness Significant cognitive impairment * Control Group History of addiction Current or previous Diagnostic and Statistical Manual (DSM-5) diagnosis Serious mental illness Significant cognitive impairment

Design outcomes

Primary

Measure	Time frame
Gene polymorphisms identified through polymerase chain reaction using fluorescent primers and restriction fragment length polymorphism analysis	Assessed at Enrollment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026